Trial · NCT06332612
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cell Viability | 8 months | Cell Viability by MTT Assay Unit: Percentage Assessment of cell viability will be reported as a percentage of untreated control cells. |
| Primary | Cytotoxicity | 8 Months | Cytotoxicity Unit: Percentage Measurement of cytotoxicity will be presented as a percentage relative to untreated control cells. |
| Primary | Morphological Changes Cell Shape | 8months | Unit: Qualitative description Cell shape alterations will be described qualitatively based on microscopic observations. |
| Primary | Morphological Change Cell Density | 8 months | Unit: Cells per unit area Changes in cell density will be quantified and reported as cells per unit area. Sub-Measure 3: Extracellular Matrix (ECM) Structure Unit: Qualitative description Alterations in ECM structure will be qualitatively assessed. |
| Primary | Morphological Change Extracellular Matrix (ECM) Structure | 8 months | Extracellular Matrix (ECM) Structure Unit: Qualitative description Alterations in ECM structure will be qualitatively assessed. |
| Primary | Cell Migration Assays | 8months | Unit: Distance migrated (micrometers) The extent of cell migration will be quantified as the distance migrated from the original point. |
| Primary | Cell Invasion Assays | 8 months | Unit: Invaded area (e.g., square millimeters) Assessment of cell invasion will be presented as the invaded area relative to untreated control cells. |
| Primary | Apoptosis Analysis | 8months | Unit: Percentage Apoptotic cells will be quantified and reported as a percentage of the total cell population. |
| Primary | Assess Signaling pathway with optimal metformin concentration | 9 months | To evaluate the effect of TGF-beta Smad 2/3 and wnt/b-catenin signaling pathways in vitro |
| Secondary | Clinical Oral Mucosal Characteristics | 9 months | Unit: Descriptive score (based on a scale ranging from 0 to 3 (normal to severe).0=No changes 1=Soreness 2=Soreness and ulceration 3=Soreness, ulceration and ability to use a liquid diet only |
| Secondary | Patient Burning sensation pain | 9 months | Unit: Units on a scale (Verbal numeric rating scale graded on a 10-point scale from 0 to 10, where 0 indicated no burning sensation while 10 represented the worst burning sensation) |
| Secondary | Patient Mouth Opening | 9 months | Unit: Millimeters on a scale of Grade 0 = \> 35 mm, Grade1= 26-35mm, Grade 2= 15-25mm, Grade 3: \< 10mm |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06332612/registered